HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giclas, P. C. Articles by Olson, M. S. Search for Related Content PubMed Articles by Giclas, P. C. Articles by Olson, M. S.

In Vitro Activation of Complement by Isolated Human Heart Subcellular Membranes¹

From the Department of Pediatrics, National Jewish Hospital & Research Center, Denver, Colorado 80206 and the Departments of Pathology and Biochemistry, University of Texas Health Center at San Antonio, San Antonio, Texas 78284

Abstract

Activation of human complement (C) occurred in vitro when mitochondrial membranes isolated from normal human heart tissue were incubated with normal human serum. This activation, as measured by C3 depletion, was not completely inhibited by blocking classical pathway activity in serum treated with EGTA, in C2-deficient serum, or in C1-depleted serum, nor in serum heated at 50°C for 30 min to block the alternative pathway, but it could be prevented by blocking the classical and the alternative pathway simultaneously with EDTA, or by treating heated serum (50°C, 30 min) with EGTA. Factor B was converted in normal serum as well as in EGTA-treated serum, but not in EDTA-treated serum. Mitochondrial membranes had no direct enzymatic or other activity that could inactivate functionally or highly purified C4 or C3, but the membranes could bind and activate C1 either in serum or in functionally pure C1 preparations. C4 also bound to the mitochondrial membranes only in the presence of C1. These data suggest that the activation of C by heart subcellular membranes involved both the classical and the alternative pathways, that the mitochondrial membrane preparations were capable of forming stable complexes with C1 and C4, but not C3, and that the mitochondrial membrane preparations did not contain enzymes or have inherent properties that could directly cause C3 conversion.

Footnotes

¹ This investigation was supported by Grant HL-20394 from the National Institutes of Health, Bethesda, Maryland.

This article has been cited by other articles:

				P. Aukrust, L. Gullestad, K. T. Lappegard, T. Ueland, H. Aass, L. Wikeby, S. Simonsen, S. S. Froland, and T. E. Mollnes Complement Activation in Patients With Congestive Heart Failure: Effect of High-Dose Intravenous Immunoglobulin Treatment Circulation, September 25, 2001; 104(13): 1494 - 1500. [Abstract] [Full Text] [PDF]

				V. A. Fadok, D. L. Bratton, L. Guthrie, and P. M. Henson Differential Effects of Apoptotic Versus Lysed Cells on Macrophage Production of Cytokines: Role of Proteases J. Immunol., June 1, 2001; 166(11): 6847 - 6854. [Abstract] [Full Text] [PDF]

				J. Frenette, B. Cai, and J. G. Tidball Complement Activation Promotes Muscle Inflammation during Modified Muscle Use Am. J. Pathol., June 1, 2000; 156(6): 2103 - 2110. [Abstract] [Full Text] [PDF]

				C. Caliezi, W. A. Wuillemin, S. Zeerleder, M. Redondo, B. Eisele, and C. E. Hack C1-Esterase Inhibitor: An Anti-Inflammatory Agent and Its Potential Use in the Treatment of Diseases Other Than Hereditary Angioedema Pharmacol. Rev., March 1, 2000; 52(1): 91 - 112. [Abstract] [Full Text] [PDF]

				J. Sonntag, M. H Wagner, E. Strauss, and M. Obladen Complement and contact activation in term neonates after fetal acidosis Arch. Dis. Child. Fetal Neonatal Ed., March 1, 1998; 78(2): 125F - 128. [Abstract] [Full Text]

				S. DeCarvalho Immunologic Aspects of Heart Disease Angiology, July 1, 1982; 33(7): 427 - 441. [Abstract] [PDF]